Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement.
Eur J Neurol
; 27(11): 2378-2380, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-707056
ABSTRACT
Miller-Fisher syndrome (MFS) is classified as a variant of Guillain-Barré syndrome (GBS), accounting for 5%-25% of all GBS cases. Since the coronavirus disease-2019 (COVID-19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS-CoV-2 infection test.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Miller Fisher Syndrome
/
COVID-19
/
Nervous System Diseases
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
/
Variants
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Eur J Neurol
Journal subject:
Neurology
Year:
2020
Document Type:
Article
Affiliation country:
Ene.14473
Similar
MEDLINE
...
LILACS
LIS